证券代码：301281 证券简称：科源制药 公告编号：2025-066 山东科源制药股份有限公司 第四届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东科源制药股份有限公司（以下简称"公司"）第四届监事会第十次会议 通知已于 2025 年 9 月 9 日通过电子邮件方式送达全体监事，经全体监事一致同 意，本次会议已豁免通知期限要求。会议于 2025 年 9 月 12 日以现场表决方式在 公司会议室召开。本次会议应出席监事 3 名，实际出席监事 3 名。会议由监事会 主席马一先生主持，公司高管列席本次会议。本次会议的召开符合《中华人民共 和国公司法》等法律、法规、规范性文件和《公司章程》的有关规定，会议合法、 有效。 二、监事会会议审议情况 （一）审议通过了《关于豁免公司第四届监事会第十次会议通知期限的议案》 根据《公司章程》等有关规定，决定豁免第四届监事会第十次会议通知期限， 并于 2025 年 9 月 12 日召开第四届监事会第十次会议。 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 表决结 ...

证券代码：301281 证券简称：科源制药 公告编号：2025-065 山东科源制药股份有限公司 第四届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东科源制药股份有限公司（以下简称"公司"）第四届董事会第十二次会 议通知已于 2025 年 9 月 9 日通过电子邮件方式送达全体董事，经全体董事一致 同意，本次会议已豁免通知期限要求。会议于 2025 年 9 月 12 日以现场和通讯表 决相结合方式在公司会议室召开。本次会议应出席董事 7 名，实际出席董事 7 名，邹晓虹先生、武滨先生通过通讯方式参会。会议由董事长高春坡先生召集并 主持，公司监事、高级管理人员列席了会议。本次会议的召开和表决程序符合《中 华人民共和国公司法》等法律、法规、规范性文件和《公司章程》的有关规定， 会议合法、有效。经公司全体董事审议通过如下议案： 二、董事会会议审议情况 （一）审议通过了《关于豁免公司第四届董事会第十二次会议通知期限的 议案》 根据《公司章程》等有关规定，决定豁免第四届董事会第十二次会议通知期 限，并于 2025 ...

证券代码：301281 证券简称：科源制药 公告编号：2025-064 山东科源制药股份有限公司 关于发行股份购买资产项目收到国家市场监督管理总局《经 营者集中反垄断审查不实施进一步审查决定书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）拟通过发行股份方式购买 山东宏济堂制药集团股份有限公司99.42%股权，同时募集配套资金（以下简称"本 次交易"）。本次交易需经过国家市场监督管理总局反垄断局的审查方可实施。 公司本次交易尚需履行深圳证券交易所审核通过并经中国证券监督管理委 员会予以注册等程序。本次交易最终能否经深圳证券交易所审核通过并经中国证 券监督管理委员会予以注册等尚存在不确定性。公司将积极推进相关工作，并严 格按照有关规定及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 山东科源制药股份有限公司 董事会 本次交易于近日收到国家市场监督管理总局出具的《经营者集中反垄断审查 不实施进一步审查决定书》（反执二审查决定【2025】524号），决定不实施进 一步审查。 ...

Major Events - Kweichow Moutai's controlling shareholder obtained a loan of 2.7 billion yuan to increase holdings [1] - SMIC is actively promoting the purchase of 49% equity in SMIC North, but the transaction plan is still under discussion [1] - Guokai Microelectronics is advancing the issuance of shares and cash payment for asset acquisition and fundraising [1] - Aerospace Hongtu signed a strategic cooperation agreement with Pakistan, but the formal contract signing remains uncertain [1] - Sinopec announced a cash dividend of 0.088 yuan per share (before tax) for A-shares [1] - Hikvision's chairman proposed a mid-2025 dividend plan of 4 yuan for every 10 shares [1] - Anzheng Fashion reported no undisclosed major events [1] - China State Construction is acquiring equity in a Shanghai real estate project for approximately 15.478 billion yuan [1] - Guokai Co., Ltd. changed its stock name to Guokai Electronics [1] - Kailuan Co. completed the change in the equity structure of China Cinda [1] - Unification Co. completed the change in the equity structure of its controlling shareholder [1] - ST Xin Dongli's stock may face delisting risk warning [1] - Jinlang Technology reported normal recent operations with no significant changes in the internal and external environment [1] - Sungrow Power Supply confirmed normal operations with no undisclosed major events [1] - Tiantong Co. reported normal production and operations with no significant changes [1] - Keyuan Pharmaceutical received a decision letter on the anti-monopoly review without further examination [1] - Zhizheng Co. was approved to issue shares for asset acquisition and fundraising [1] - Amlogic plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Digital Certification's controlling shareholder changed to Beijing Data Group [1] - ST Songfa signed a contract for two 30.6 million-ton ultra-large crude oil tankers with Hengli Shipbuilding [1] - Guangqi Technology signed a contract worth 1.278 billion yuan for the mass production of metamaterials [1] - Hongrun Construction won a bid for the Ningbo Ring City South Road East Extension Phase I project with a bid price of 388 million yuan [1] Performance - Muyuan Foods reported sales revenue of 11.85 billion yuan from live pigs in August, a year-on-year decrease of 12.30% [1] - Ankai Bus's cumulative production increased by 68.06% this year [1] - Shuguang Co. reported a 45.58% increase in axle sales in August [1] - Jinxinnong reported sales revenue of 121 million yuan from live pigs in August [1] Buyback - Yingke Medical adjusted the upper limit of its share repurchase price from 26.51 yuan per share to 41.88 yuan per share [2]

Core Insights - The industrial economy is prioritized as the "number one project" in Shanghe County, contributing 32.5% to GDP growth in 2024, making it the primary driver of economic growth [1] Group 1: Industrial Development - The number of enterprises with output exceeding 100 million yuan has increased to 51, with Lino Pharmaceutical and Jins河面业 both surpassing 1 billion yuan in output [1] - Farui Sodium Welding Equipment has been recognized as a national-level specialized and innovative "little giant" enterprise [1] - Lino Pharmaceutical and Keyuan Pharmaceutical have successfully gone public [1] Group 2: Project Implementation - In the past three years, Shanghe County has implemented 158 key industrial projects, with several projects like Hongri Pharmaceutical and Huagong Laser completed and put into production [1] - Projects such as Hongjitang Pharmaceutical and Mashi Automotive Wiring Harness are accelerating construction [1] - New projects including Hengrui Pharmaceutical and Hongtian Clothing have been signed and established [1]

Group 1 - The company, Koyuan Pharmaceutical, plans to acquire 99.42% equity of Shandong Hongjitang Pharmaceutical Group through a share issuance and raise matching funds [1] - The transaction requires approval from the State Administration for Market Regulation and has received a decision not to conduct further antitrust review [1] - The acquisition still needs to pass the Shenzhen Stock Exchange review and be registered with the China Securities Regulatory Commission [1]

科源制药公告，公司拟通过发行股份方式购买山东宏济堂制药集团股份有限公司99.42%股权，同时募 集配套资金。本次交易已收到国家市场监督管理总局出具的《经营者集中反垄断审查不实施进一步审查 决定书》，决定不实施进一步审查。本次交易尚需履行深圳证券交易所审核通过并经中国证券监督管理 委员会予以注册等程序，最终能否成功存在不确定性。 ...

公司本次交易尚需履行深圳证券交易所审核通过并经中国证券监督管理委 员会予以注册等程序。本次交易最终能否经深圳证券交易所审核通过并经中国证 券监督管理委员会予以注册等尚存在不确定性。公司将积极推进相关工作，并严 格按照有关规定及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 山东科源制药股份有限公司 关于发行股份购买资产项目收到国家市场监督管理总局《经 营者集中反垄断审查不实施进一步审查决定书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）拟通过发行股份方式购买 山东宏济堂制药集团股份有限公司99.42%股权，同时募集配套资金（以下简称"本 次交易"）。本次交易需经过国家市场监督管理总局反垄断局的审查方可实施。 本次交易于近日收到国家市场监督管理总局出具的《经营者集中反垄断审查 不实施进一步审查决定书》（反执二审查决定【2025】524号），决定不实施进 一步审查。 证券代码：301281 证券简称：科源制药 公告编号：2025-064 山东科源制药股份有限公司 董事会 2025 年 9 月 5 ...

2025 年半年度持续督导跟踪报告 | 保荐人名称：中信建投证券股份有限公司 | 被保荐公司简称：科源制药 | | --- | --- | | 保荐代表人姓名：杨慧泽 | 联系电话：010-56051417 | | 保荐代表人姓名：王辉 | 联系电话：010-56052337 | 中信建投证券股份有限公司 关于山东科源制药股份有限公司 | （2）发表非同意意见所涉及问题及结论意见 | 无 | | --- | --- | | 7、向深交所报告情况（现场检查报告除外） | | | （1）向深交所报告的次数 | 无 | | （2）报告事项的主要内容 | 不适用 | | （3）报告事项的进展或者整改情况 | 不适用 | | 8、关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 无 | | （2）关注事项的主要内容 | 不适用 | | （3）关注事项的进展或者整改情况 | 不适用 | | 9、保荐业务工作底稿记录、保管是否合规 | 是 | | 10、对上市公司培训情况 | | | （1）培训次数 | 次 1 | | （2）培训日期 | 年 月 日 2025 6 4 | | （3）培训的主要内容 | 《上 ...

Core Viewpoint - In the recent five trading days, significant shareholders of 7 companies increased their holdings, totaling 59.71 million shares and an investment amount of 306 million yuan, while 96 companies saw a reduction in holdings amounting to 7.696 billion yuan [1] Group 1: Shareholder Activity - A total of 7 companies had significant shareholder increases, with the highest increase from Hubei Yihua, which saw an increase of 7.3371 million shares and an investment of 97.5834 million yuan [1][2] - Shanghai Laishi followed with an increase of 12.4132 million shares and an investment of 85.0908 million yuan, while Sanfeng Environment had an increase of 4.4733 million yuan [1][2] - The majority of the increased holdings were concentrated in the pharmaceutical and electronic industries, with 2 stocks each [1] Group 2: Market Performance - The average increase in stock prices for companies with shareholder increases was 3.25% over the five days, which was weaker than the Shanghai Composite Index performance during the same period [1] - Notable stock price increases included Wanrun Shares and Hongli Zhihui, with increases of 7.37% and 4.01%, respectively [1] Group 3: Financial Performance - Among the stocks with significant shareholder increases, three have reported their semi-annual results, with Koyuan Pharmaceutical showing the highest net profit growth of 18.26% year-on-year [2]